REVITALIZE: Reducing Fatigue in Ovarian Cancer on PARP Inhibitors
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This study tests whether a program called REVITALIZE can help reduce severe fatigue in women with ovarian cancer who are currently taking a PARP inhibitor (a type of targeted therapy). The goal is to see if this approach improves daily energy and quality of life.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older and have ovarian, fallopian tube, or primary peritoneal cancer.
- You've finished your main treatment (surgery and chemotherapy).
- You've been on a PARP inhibitor (like olaparib, niraparib, or rucaparib) for at least 2 months and plan to keep taking it for 7 more months.
- You feel fatigue (tiredness) that is at least moderately bothersome (score of 4 or more out of 10).
- You are able to speak English and are willing to use a special pill bottle that tracks when you take your medication.
- Your overall health is good enough to perform daily activities (ECOG performance status 0–2).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two targeted drugs, cirtuvivint and olaparib, for a specific type of ovarian cancer that no longer responds to platinum chemotherapy. It may be an option if you have a BRCA mutation or HRD-positive tumor and have already tried a PARP inhibitor.
This trial tests whether a supervised exercise and nutrition program can improve well-being for people with ovarian cancer who are taking a maintenance drug called a PARP inhibitor after finishing their first round of chemotherapy. Participation may help manage side effects and support overall health.
This trial tests whether using a patient-reported outcomes tool can help manage fatigue during treatment for ovarian cancer. It aims to improve how you feel during therapy.
This study looks at how eating habits may affect the outlook for people with ovarian cancer who are taking a maintenance drug called a PARP inhibitor. By understanding your diet, researchers hope to find ways to improve treatment results.
This trial studies how well older adults (70+) with advanced ovarian cancer tolerate PARP inhibitors in real-world care. It aims to see if the standard dose works for this age group.
This study looks at how PARP inhibitor maintenance therapy affects survival in people with ovarian, fallopian tube, or peritoneal cancer. It compares outcomes for those newly diagnosed at an advanced stage and those with a first recurrence that responded to platinum chemotherapy.
Hear when a new Ovarian cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.